FDA Expands Approval of Treatment for Generalized Pustular Psoriasis

The US Food and Drug Administration has approved spesolimab-sbzo, an interleukin -36 receptor antagonist, for the treatment of generalized pustular psoriasis in adults and in pediatric patients aged ≥ 12 years who weigh ≥ 40 kg, according to an announcement from the manufacturer., the product is an injectable antibody that blocks the IL-36 receptor, a key part of the pathway shown to be involved in the cause of GPP, which is rare and is a potentially-life-threatening disease.

Spesolimab-sbzo is currently available in 48 countries, according to the Boehringer Ingelheim release, which states that the approval makes it the firstAll material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

In an unusual move, FDA postpones approval decision for Lilly’s Alzheimer’s drugBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »

Wegovy, the weight-loss medication, gets FDA approval for use as heart disease prevention drugWegovy has been FDA-approved for heart disease prevention. The semaglutide, originally approved for weight loss, is now approved to reduce the risk of cardiovascular death, heart attack and stroke.
Source: FoxBusiness - 🏆 458. / 53 Read more »

Wegovy weight-loss medication gets FDA approval for use as heart disease prevention drugThe injectable semaglutide from Novo Nordisk was shown to reduce risk of cardiovascular death, heart attack and stroke.
Source: FOXLA - 🏆 445. / 53 Read more »